Subcutaneous Enzyme Formulation with Hyaluronidase Dispersing Agent
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for lysosomal storage diseases rely on intravenous enzyme replacement therapies, which are complex, require specialized equipment, and pose challenges such as infusion-related hypersensitivities and limited patient compliance, especially for pediatric or infant patients.
Innovation Solution
Development of compositions and methods for subcutaneous or transdermal delivery of lysosomal storage disorder replacement enzymes, using a stable formulation with a dispersing agent like hyaluronidase to facilitate delivery, improving stability and reducing adverse reactions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If intravenous enzyme replacement therapy is used, then therapeutic effect is achieved, but treatment complexity and risk of hypersensitivity increase
Solution Approach 1:
The patent uses hyaluronidase as a dispersing agent intermediary to facilitate subcutaneous delivery of replacement enzymes. This mediator breaks down hyaluronic acid in the subcutaneous tissue, creating pathways for enzyme distribution and absorption, thereby enabling effective therapy without requiring intravenous access or complex infusion equipment.
Solution Approach 2:
The invention replaces the mechanical intravenous infusion system with a simpler subcutaneous injection system. By using dispersing agents to enable effective enzyme delivery through subcutaneous tissue, the complex mechanical infrastructure of IV pumps and catheters is substituted with a straightforward injection approach.
2Reliability
If intravenous enzyme replacement therapy is used, then therapeutic effect is achieved, but risk of hypersensitivity and infection increases
Solution Approach 1:
Hyaluronidase acts as a mediator that facilitates gentle enzyme distribution through subcutaneous tissue, avoiding the direct intravenous exposure that triggers hypersensitivity reactions. The dispersing agent enables controlled release and distribution, reducing the likelihood of acute immune responses.
Solution Approach 2:
The invention changes the administration parameter from intravenous to subcutaneous delivery. This route modification, combined with the use of dispersing agents, alters the pharmacokinetic profile to reduce peak plasma concentrations and associated hypersensitivity risks while maintaining therapeutic efficacy through sustained enzyme activity.
3Ease of operation
If subcutaneous delivery with dispersing agent is used, then ease of administration is improved, but formulation stability challenges arise
Solution Approach 1:
The patent creates a composite formulation combining replacement enzymes with hyaluronidase dispersing agents and stabilizing excipients. This composite structure addresses stability challenges by integrating multiple functional components that work synergistically to maintain enzyme activity during storage and after subcutaneous administration.
Solution Approach 2:
The invention optimizes formulation parameters including pH, ionic strength, and temperature to enhance stability. By carefully controlling these parameters and using stabilizing excipients, the formulation maintains enzyme integrity during storage while enabling effective subcutaneous delivery with dispersing agents.
4Ease of operation
If subcutaneous delivery is used, then patient compliance is improved, but enzyme distribution efficiency may be reduced
Solution Approach 1:
Hyaluronidase serves as a mediator that enhances enzyme distribution efficiency in subcutaneous tissue by breaking down hyaluronic acid barriers. This intermediary function ensures thorough tissue penetration and systemic absorption, compensating for the potentially limited distribution capacity of subcutaneous delivery compared to intravenous routes.
Solution Approach 2:
The dispersing agent performs preliminary action by pre-processing the subcutaneous tissue environment before enzyme delivery. By预先 breaking down hyaluronic acid and creating distribution pathways, the mediator ensures efficient enzyme spread and absorption, maximizing the productivity of subcutaneous administration.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The subcutaneous or transdermal delivery method provides a more convenient and effective treatment option with reduced hypersensitivity risks, extended plasma half-life of enzymes, and improved patient compliance, while maintaining enzymatic activity during storage.
Implementation Method 1
compositions comprising a lysosomal storage disorder replacement enzyme (LSDRE) and a dispersing agent, wherein the LSDRE and the dispersing agent are in a stable formulation
Implementation Method 2
the dispersing agent is hyaluronidase and is present at a concentration of 1-1000 U, 100-1000 U, 250-1000 U, 1-5 U, 5-10 U, 10-50 U, 50-100 U, 100-200 U, 200-300 U, 300-500 U, or 500-1000 U per unit dose
Data Source
AI summary
Provided herein are compositions containing a lysosomal storage disorder replacement enzyme (LSDRE) and a dispersing agent for subcutaneous injection for treatment of lysosomal storage diseases. Kits and methods of treatment are also provided.